Oral UTI Antibiotic Approved
FDA Approves GSK and Spero's Oral Carbapenem for Complicated Urinary Tract Infections
Key Points
The approval was based on a Phase 3 program that, according to one report, involved roughly 1,700 hospitalized patients comparing oral Utebzi to IV imipenem-cilastatin.
In PIVOT-PO, the study’s primary ‘overall response’/success metric was defined as a composite of clinical cure plus microbiological eradication at the test-of-cure visit (in addition to reporting the overall success rates).
The trial compared specific regimens: tebipenem pivoxil 600 mg taken orally versus imipenem-cilastatin 500 mg given intravenously.
GSK said the development of tebipenem pivoxil received partial support from the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) through federal funding.
The FDA has approved Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic ever cleared for use in the United States. MarketScreener reported the drug is approved for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no other oral treatment options.
GSK developed the drug alongside Spero Therapeutics, which originally licensed it from Japan. Utebzi is expected to reach U.S. patients by the end of 2026. The approval marks a major shift in how doctors can treat resistant infections — no hospital stay or IV drip required.
A Decades-Long Drug Journey From Japan to FDA Approval
Tebipenem pivoxil was first approved in Japan in 2009 under the brand name Orapenem, used in children for respiratory infections. Spero Therapeutics later acquired global rights and began testing it in U.S. adults with complicated urinary tract infections.
The road was not smooth. The FDA rejected Spero's application in 2022, saying the trial data was not enough. GSK then stepped in, paying $66 million upfront to take over development. Spero could earn up to $525 million more in milestone payments, plus low-double-digit royalties on U.S. sales.
Trial Data: Oral Pill Matches IV Treatment in Head-to-Head Study
The approval rests on the Phase 3 PIVOT-PO trial, which enrolled roughly 1,700 hospitalized patients. Researchers compared Utebzi — taken as a 600 mg oral tablet — against imipenem-cilastatin 500 mg given by IV. The main goal was a composite of clinical cure plus full elimination of the bacteria.
Overall success was 58.5% with the oral drug versus 60.2% with the IV comparator. The difference fell within the pre-set non-inferiority margin of -12.5%, confirming the pill works as well as the IV. Side effects were mild — diarrhea in about 5% of patients and headache in about 3%.
Oral Carbapenems Could Cut Hospital Stays and Save Thousands Per Patient
Carbapenems are among the most powerful antibiotics doctors have. Until now, they only came as IV drugs, forcing patients to stay in a hospital or use a PICC line at home. An oral version changes that. GSK's Chief Scientific Officer Tony Wood said the drug offers patients "a way to recover at home while easing the strain on hospital resources."
The cost savings could be significant. Avoiding a five-day hospital stay for IV treatment can save between $8,000 and $15,000 per patient, according to research cited in health policy analysis. Complicated UTIs cause nearly 3 million hospitalizations in the U.S. each year, making the market potential large. BARDA, the U.S. government's medical research arm, helped fund the drug's development.
Stewardship Concerns Shadow an Otherwise Celebrated Approval
Not everyone is celebrating without reservation. Public health experts warn that an easy-to-take oral carbapenem could be over-prescribed. Carbapenems are considered a last-resort class of antibiotics. Overuse in outpatient settings could speed up resistance, eventually rendering the whole class useless against superbugs.
Industry analysts at firms including Jefferies caution that the drug's restrictive label — limited to patients with no other oral options — may cap early sales. Still, Spero CEO Ankit Mahadevia called the approval "a transformative moment," and patient advocates say the drug will help rural patients who cannot easily access hospital infusion centers.
Sentiment
Mostly PositivePublishers
10
Articles
41
Reach
51
